Clinical Trial Update: A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy [Phase 1, Phase 2]

View source ↗

Summary

Presurgical Phase 1/2 trial evaluating REGN5678, an Anti-PSMA x CD28 bispecific, in high-risk localized prostate cancer patients planned for radical prostatecto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• REGN5678

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Cancer, Radical Prostatectomy | Phase 1, Phase 2 | Status: RECRUITING